MoCRA - FDA and Cosmetics regulation
MoCRA: A New Era for Cosmetic Regulation with AF Pharma's Support
For over a decade, the Personal Care Products Council (PCPC) and its member companies have tirelessly worked alongside bipartisan congressional leaders and a wide range of stakeholders to enhance the U.S. Food and Drug Administration's (FDA) regulatory authority. Their goal has been to provide consumers with the safety assurances they expect and deserve when it comes to cosmetics. As part of their ongoing commitment to cosmetics reform, PCPC and its members have supported a set of principles that align with protections applied to other FDA-regulated products. However, the real game-changer arrived on December 29, 2022, when President Biden signed the Consolidated Appropriations Act 2023 into law, which included the Modernization of Cosmetics Regulation Act (MoCRA) of 2022. This historic legislation equips the FDA with additional tools to ensure cosmetics' safety and protect public health, all while bolstering consumer confidence in the products they use daily. MoCRA also brings the FDA's oversight of the beauty and personal care sector more in line with other categories the Agency regulates and contributes to global regulatory alignment.
What is MoCRA?
The Modernization of Cosmetics Regulation Act (MoCRA) is a groundbreaking piece of legislation that has transformed the cosmetics industry. This long-awaited act empowers the FDA with the authority and tools needed to regulate cosmetics more effectively. MoCRA's primary goal is to ensure the safety of cosmetics and enhance consumer trust in these products. It achieves this by aligning cosmetics regulations with those applied to other FDA-regulated items and facilitating global regulatory alignment.
MoCRA's Bipartisan Effort:
What sets MoCRA apart is its truly bipartisan nature. It emerged as a result of a collaborative and compromise-driven effort that brought together a diverse group of stakeholders. These stakeholders worked in the spirit of cooperation to advance science-based reforms. MoCRA reflects a commitment to putting consumer safety and industry responsibility at the forefront, and it has garnered support from various quarters.
AF Pharma's Role in Supporting MoCRA Applications:
AF Pharma stands as a reliable ally in the changing landscape of cosmetics regulation brought about by MoCRA. As the FDA begins developing implementing regulations for MoCRA, AF Pharma provides invaluable support and industry insight. By anticipating member and key stakeholder needs and assisting member companies throughout the regulatory process, AF Pharma ensures a smooth transition for businesses in the cosmetics sector. AF Pharma's expertise and commitment to regulatory compliance make them a trusted partner in navigating the evolving regulatory environment.
With the signing of the Modernization of Cosmetics Regulation Act (MoCRA), the cosmetics industry has entered a new era of heightened safety standards and regulatory alignment. This historic legislation reflects a bipartisan commitment to consumer safety and industry responsibility. As the FDA works to implement MoCRA, AF Pharma plays a crucial role in supporting manufacturers and ensuring a smooth transition. This landmark legislation will not only bolster consumer confidence but also enhance the overall safety and quality of cosmetic products, making them better than ever before.